Market Cap 14.90B
Revenue (ttm) 4.03B
Net Income (ttm) 789.50M
EPS (ttm) N/A
PE Ratio 15.94
Forward PE 15.70
Profit Margin 19.59%
Debt to Equity Ratio 0.55
Volume 1,776,700
Avg Vol 3,477,284
Day's Range N/A - N/A
Shares Out 222.85M
Stochastic %K 56%
Beta 0.55
Analysts Sell
Price Target $68.67

Company Profile

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, an...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 508 263 2900
Address:
250 Campus Drive, Marlborough, United States
ZacksResearch
ZacksResearch Jul. 10 at 12:40 PM
$HOLX: Is the GYN Surgical business well-positioned or facing headwinds? ๐Ÿค” Despite strong international growth and recent strategic acquisitions, Hologic shares have slid 8.7% YTD, trading at a discounted forward P/E of 14.85 vs. the industry average of 28.39. However, the stock holds a Zacks Rank #4 (Sell), with bearish fiscal 2025-2026 earnings estimates. Discover if HOLX is a hidden gem or a risky bet ๐Ÿ‘‰ https://www.zacks.com/stock/news/2570811/hologics-gyn-surgical-dominance-whats-powering-the-road-ahead?cid=sm-stocktwits-2-2570811-body-1132&ADID=SYND_STOCKTWITS_TWEET_2_2570811_BODY_1132
0 ยท Reply
ZacksResearch
ZacksResearch Jul. 10 at 11:30 AM
$HOLXโ€™s surgical biz is quietly dominating โ€” hereโ€™s why it matters ๐Ÿฅ๐Ÿ“ˆ GYN Surgical is gaining steam with Fluent Pro, aggressive global expansion, and strategic acquisitions all driving momentum. Find out what could power HOLXโ€™s next leg higher ๐Ÿ‘‰ https://www.zacks.com/stock/news/2570811/hologics-gyn-surgical-dominance-whats-powering-the-road-ahead?cid=sm-stocktwits-2-2570811-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2570811_TEASER
0 ยท Reply
JarvisFlow
JarvisFlow Jul. 9 at 12:30 PM
Citigroup updates rating for Hologic ( $HOLX ) to Buy, target set at 60 โ†’ 80.
0 ยท Reply
JarvisFlow
JarvisFlow Jul. 8 at 1:01 PM
Evercore ISI Group has updated their rating for Hologic ( $HOLX ) to In-Line with a price target of 68.
0 ยท Reply
ZacksResearch
ZacksResearch Jul. 8 at 12:56 PM
$HOLX struggles amid macro headwinds โ€” is it still worth the risk? ๐Ÿ˜Ÿ ๐Ÿ“‰ Stock down 10.8% YTD, lagging industry & S&P 500 ๐Ÿ” Earnings estimates slipping; Zacks Rank #4 (Sell) ๐Ÿ’ธ Tariff pressures from manufacturing in Costa Rica & China outlook weigh heavy Full analysis here ๐Ÿ‘‰ https://www.zacks.com/stock/news/2567029/is-hologic-stocks-low-valuation-an-opportunity-or-a-value-trap?cid=sm-stocktwits-2-2567029-body-897&ADID=SYND_STOCKTWITS_TWEET_2_2567029_BODY_897
0 ยท Reply
ZacksResearch
ZacksResearch Jul. 8 at 11:39 AM
$HOLX looks cheapโ€ฆ but is it for a reason? It trades below peers on P/S, yet EPS is falling, Breast Health sales are weak, and China adds more uncertainty. Opportunity or value trap? Full breakdown here ๐Ÿ‘‰ https://www.zacks.com/stock/news/2567029/is-hologic-stocks-low-valuation-an-opportunity-or-a-value-trap?cid=sm-stocktwits-2-2567029-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2567029_TEASER
0 ยท Reply
ZacksResearch
ZacksResearch Jul. 2 at 2:21 PM
$HOLX Molecular Diagnostics shines amid setbacks! โœจ ๐Ÿš€ 7.8% growth in the second quarter excluding COVID-19-related sales, despite USAID funding cuts impacting HIV testing. ๐Ÿ”ฌ Focus on expanding test adoption and leveraging innovative assays like BV/CV/TV for growth. Discover the full growth strategy here ๐Ÿ‘‰ https://www.zacks.com/commentary/2560330/hologic-faces-molecular-drag-but-heres-why-its-not-a-major-concern?cid=sm-stocktwits-2-2560330-body-623&ADID=SYND_STOCKTWITS_TWEET_2_2560330_BODY_623
0 ยท Reply
ZacksResearch
ZacksResearch Jul. 2 at 12:37 PM
Molecular slowdown at $HOLX? Here's why itโ€™s not a red flag ๐Ÿ‘€ Molecular Diagnostics is still showing solid growth โ€” new assays and broader test adoption are helping cushion the impact of funding pressures. Full breakdown here ๐Ÿ‘‰ https://www.zacks.com/stock/news/2560330/hologic-faces-molecular-drag-but-heres-why-its-not-a-major-concern?cid=sm-stocktwits-2-2560330-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2560330_TEASER
0 ยท Reply
ZacksResearch
ZacksResearch Jun. 25 at 2:26 PM
$HOLX bucks the trend with a 5.3% rise in 3 months, while the industry dipped 8.6%! ๐Ÿ“ˆ โšก Strong cash flow supports approximately $3.6B share buybacks, including $200M in Q2 FY2025, and strategic M&A ๐Ÿฉบ Recent acquisitions boosting revenue and operating margins ๐Ÿ” Positioned well with a forward earnings multiple of 14.66X Discover how HOLX is reshaping its growth story ๐Ÿ‘‰ https://www.zacks.com/commentary/2553365/how-hologic-leverages-its-financial-firepower-to-drive-long-term-value?cid=sm-stocktwits-2-2553365-body-82&ADID=SYND_STOCKTWITS_TWEET_2_2553365_BODY_82
0 ยท Reply
ZacksResearch
ZacksResearch Jun. 25 at 12:15 PM
$HOLX is putting its money where its mouth is ๐Ÿ’ฐ๐Ÿ“ˆ Strong profitability is fueling billions in buybacks and acquisitions โ€” a clear play to drive long-term EPS growth. See how this strategy could unlock more value ๐Ÿ‘‰ https://www.zacks.com/stock/news/2553365/how-hologic-leverages-its-financial-firepower-to-drive-long-term-value?cid=sm-stocktwits-2-2553365-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2553365_TEASER
0 ยท Reply
Latest News on HOLX
Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday?

May 27, 2025, 3:48 PM EDT - 6 weeks ago

Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday?


Hologic: Soft Performance, But Cheap Enough

May 6, 2025, 5:39 PM EDT - 2 months ago

Hologic: Soft Performance, But Cheap Enough


Hologic, Inc. (HOLX) Q2 2025 Earnings Call Transcript

May 1, 2025, 8:24 PM EDT - 2 months ago

Hologic, Inc. (HOLX) Q2 2025 Earnings Call Transcript


Wayde McMillan Elected to Hologic Board of Directors

Apr 4, 2025, 4:15 PM EDT - 3 months ago

Wayde McMillan Elected to Hologic Board of Directors


Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay

Feb 18, 2025, 8:08 AM EST - 5 months ago

Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay


Hologic, Inc. (HOLX) Q1 2025 Earnings Call Transcript

Feb 5, 2025, 10:06 PM EST - 5 months ago

Hologic, Inc. (HOLX) Q1 2025 Earnings Call Transcript


Hologic: Reasonably, But Not Compellingly Valued

Jan 17, 2025, 1:28 PM EST - 6 months ago

Hologic: Reasonably, But Not Compellingly Valued


Hologic Completes Acquisition of Gynesonics, Inc.

Jan 6, 2025, 8:05 AM EST - 6 months ago

Hologic Completes Acquisition of Gynesonics, Inc.


Martin Madaus Elected to Hologic Board of Directors

Dec 9, 2024, 4:05 PM EST - 7 months ago

Martin Madaus Elected to Hologic Board of Directors


Hologic, Inc. (HOLX) Q4 2024 Earnings Call Transcript

Nov 4, 2024, 7:26 PM EST - 8 months ago

Hologic, Inc. (HOLX) Q4 2024 Earnings Call Transcript


Hologic Analysts Boost Their Forecasts After Q3 Results

Jul 30, 2024, 9:05 AM EDT - 1 year ago

Hologic Analysts Boost Their Forecasts After Q3 Results


Hologic, Inc. (HOLX) Q3 2024 Earnings Call Transcript

Jul 29, 2024, 8:40 PM EDT - 1 year ago

Hologic, Inc. (HOLX) Q3 2024 Earnings Call Transcript


Hologic Completes Acquisition of Endomagnetics Ltd

Jul 25, 2024, 8:19 AM EDT - 1 year ago

Hologic Completes Acquisition of Endomagnetics Ltd


ZacksResearch
ZacksResearch Jul. 10 at 12:40 PM
$HOLX: Is the GYN Surgical business well-positioned or facing headwinds? ๐Ÿค” Despite strong international growth and recent strategic acquisitions, Hologic shares have slid 8.7% YTD, trading at a discounted forward P/E of 14.85 vs. the industry average of 28.39. However, the stock holds a Zacks Rank #4 (Sell), with bearish fiscal 2025-2026 earnings estimates. Discover if HOLX is a hidden gem or a risky bet ๐Ÿ‘‰ https://www.zacks.com/stock/news/2570811/hologics-gyn-surgical-dominance-whats-powering-the-road-ahead?cid=sm-stocktwits-2-2570811-body-1132&ADID=SYND_STOCKTWITS_TWEET_2_2570811_BODY_1132
0 ยท Reply
ZacksResearch
ZacksResearch Jul. 10 at 11:30 AM
$HOLXโ€™s surgical biz is quietly dominating โ€” hereโ€™s why it matters ๐Ÿฅ๐Ÿ“ˆ GYN Surgical is gaining steam with Fluent Pro, aggressive global expansion, and strategic acquisitions all driving momentum. Find out what could power HOLXโ€™s next leg higher ๐Ÿ‘‰ https://www.zacks.com/stock/news/2570811/hologics-gyn-surgical-dominance-whats-powering-the-road-ahead?cid=sm-stocktwits-2-2570811-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2570811_TEASER
0 ยท Reply
JarvisFlow
JarvisFlow Jul. 9 at 12:30 PM
Citigroup updates rating for Hologic ( $HOLX ) to Buy, target set at 60 โ†’ 80.
0 ยท Reply
JarvisFlow
JarvisFlow Jul. 8 at 1:01 PM
Evercore ISI Group has updated their rating for Hologic ( $HOLX ) to In-Line with a price target of 68.
0 ยท Reply
ZacksResearch
ZacksResearch Jul. 8 at 12:56 PM
$HOLX struggles amid macro headwinds โ€” is it still worth the risk? ๐Ÿ˜Ÿ ๐Ÿ“‰ Stock down 10.8% YTD, lagging industry & S&P 500 ๐Ÿ” Earnings estimates slipping; Zacks Rank #4 (Sell) ๐Ÿ’ธ Tariff pressures from manufacturing in Costa Rica & China outlook weigh heavy Full analysis here ๐Ÿ‘‰ https://www.zacks.com/stock/news/2567029/is-hologic-stocks-low-valuation-an-opportunity-or-a-value-trap?cid=sm-stocktwits-2-2567029-body-897&ADID=SYND_STOCKTWITS_TWEET_2_2567029_BODY_897
0 ยท Reply
ZacksResearch
ZacksResearch Jul. 8 at 11:39 AM
$HOLX looks cheapโ€ฆ but is it for a reason? It trades below peers on P/S, yet EPS is falling, Breast Health sales are weak, and China adds more uncertainty. Opportunity or value trap? Full breakdown here ๐Ÿ‘‰ https://www.zacks.com/stock/news/2567029/is-hologic-stocks-low-valuation-an-opportunity-or-a-value-trap?cid=sm-stocktwits-2-2567029-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2567029_TEASER
0 ยท Reply
ZacksResearch
ZacksResearch Jul. 2 at 2:21 PM
$HOLX Molecular Diagnostics shines amid setbacks! โœจ ๐Ÿš€ 7.8% growth in the second quarter excluding COVID-19-related sales, despite USAID funding cuts impacting HIV testing. ๐Ÿ”ฌ Focus on expanding test adoption and leveraging innovative assays like BV/CV/TV for growth. Discover the full growth strategy here ๐Ÿ‘‰ https://www.zacks.com/commentary/2560330/hologic-faces-molecular-drag-but-heres-why-its-not-a-major-concern?cid=sm-stocktwits-2-2560330-body-623&ADID=SYND_STOCKTWITS_TWEET_2_2560330_BODY_623
0 ยท Reply
ZacksResearch
ZacksResearch Jul. 2 at 12:37 PM
Molecular slowdown at $HOLX? Here's why itโ€™s not a red flag ๐Ÿ‘€ Molecular Diagnostics is still showing solid growth โ€” new assays and broader test adoption are helping cushion the impact of funding pressures. Full breakdown here ๐Ÿ‘‰ https://www.zacks.com/stock/news/2560330/hologic-faces-molecular-drag-but-heres-why-its-not-a-major-concern?cid=sm-stocktwits-2-2560330-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2560330_TEASER
0 ยท Reply
ZacksResearch
ZacksResearch Jun. 25 at 2:26 PM
$HOLX bucks the trend with a 5.3% rise in 3 months, while the industry dipped 8.6%! ๐Ÿ“ˆ โšก Strong cash flow supports approximately $3.6B share buybacks, including $200M in Q2 FY2025, and strategic M&A ๐Ÿฉบ Recent acquisitions boosting revenue and operating margins ๐Ÿ” Positioned well with a forward earnings multiple of 14.66X Discover how HOLX is reshaping its growth story ๐Ÿ‘‰ https://www.zacks.com/commentary/2553365/how-hologic-leverages-its-financial-firepower-to-drive-long-term-value?cid=sm-stocktwits-2-2553365-body-82&ADID=SYND_STOCKTWITS_TWEET_2_2553365_BODY_82
0 ยท Reply
ZacksResearch
ZacksResearch Jun. 25 at 12:15 PM
$HOLX is putting its money where its mouth is ๐Ÿ’ฐ๐Ÿ“ˆ Strong profitability is fueling billions in buybacks and acquisitions โ€” a clear play to drive long-term EPS growth. See how this strategy could unlock more value ๐Ÿ‘‰ https://www.zacks.com/stock/news/2553365/how-hologic-leverages-its-financial-firepower-to-drive-long-term-value?cid=sm-stocktwits-2-2553365-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2553365_TEASER
0 ยท Reply
ZacksResearch
ZacksResearch Jun. 23 at 1:45 PM
Hologic vs CooperCompanies: Which is the better hold? ๐Ÿค” $HOLX has a strong GYN Surgical business with international momentum and financial strength, despite macro pressures. $COO sees rising earnings estimates but faces weakness in fertility. Both trade at discounted P/S ratios. See the full comparison here ๐Ÿ‘‰ https://www.zacks.com/commentary/2535251/holx-vs-coo-which-gyn-surgical-stock-is-the-better-investment-now?cid=sm-stocktwits-2-2535251-body&ADID=SYND_STOCKTWITS_TWEET_2_2535251_BODY
0 ยท Reply
ZacksResearch
ZacksResearch Jun. 23 at 12:39 PM
$HOLX vs. $COO โ€” which GYN surgical play has the edge? Demand for GYN tools is rising, but only one of these names is showing stronger growth momentum right now. Find out which stock stands out ๐Ÿ‘‰ https://www.zacks.com/stock/news/2535251/holx-vs-coo-which-gyn-surgical-stock-is-the-better-investment-now?cid=sm-stocktwits-2-2535251-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2535251_TEASER
0 ยท Reply
ZacksResearch
ZacksResearch Jun. 16 at 1:04 PM
$HOLX: Can it weather the storm despite a turbulent year ahead? ๐ŸŒฉ๏ธ Hologic's shares have dropped 10.4% over six months while the stock trades at a forward P/S of 3.42x, above its sector, with a Zacks Rank #4 (Sell). Understand the risks before investing in HOLX ๐Ÿ‘‰ https://www.zacks.com/commentary/2503122/hologics-margin-stability-amid-tariffs-whats-behind-the-confidence?cid=sm-stocktwits-2-2503122-body&ADID=SYND_STOCKTWITS_TWEET_2_2503122_BODY
0 ยท Reply
ZacksResearch
ZacksResearch Jun. 16 at 11:35 AM
Margin strength from $HOLX โ€” even with China weakness and tariffs? Diagnostic momentum and high-margin acquisitions are keeping the profit engine running. Full breakdown here ๐Ÿ‘‰ https://www.zacks.com/stock/news/2503122/hologics-margin-stability-amid-tariffs-whats-behind-the-confidence?cid=sm-stocktwits-2-2503122-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2503122_TEASER
0 ยท Reply
ZacksResearch
ZacksResearch Jun. 11 at 1:21 PM
$HOLX navigating headwinds with adjustments in core businesses ๐ŸŒ๐Ÿ’ผ ๐Ÿ“‰ Excludes $50M HIV testing business in Africa due to halted USAID funding ๐Ÿ’ฐ Facing $20M-$25M tariff-related cost hikes ๐Ÿ”ฌ Diagnostics segment momentum driven by strong demand for key assays and growing service business Discover the full analysis here ๐Ÿ‘‰ https://www.zacks.com/commentary/2494076/can-hologic-lean-on-its-strengths-in-a-tough-macroeconomic-climate?cid=sm-stocktwits-2-2494076-body&ADID=SYND_STOCKTWITS_TWEET_2_2494076_BODY
0 ยท Reply
ZacksResearch
ZacksResearch Jun. 11 at 11:31 AM
Can $HOLX weather the storm โ€” or thrive in it? Growth in Diagnostics and Breast Health service segments is helping offset global macro headwinds. Full story here ๐Ÿ‘‰ https://www.zacks.com/stock/news/2494076/can-hologic-lean-on-its-strengths-in-a-tough-macroeconomic-climate?cid=sm-stocktwits-2-2494076-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2494076_TEASER
0 ยท Reply
ZacksResearch
ZacksResearch Jun. 9 at 1:35 PM
$HOLX surges 13.3% โ€” what's fueling the rally? ๐Ÿš€ ๐Ÿ”น Hologic turned down a non-binding $16.7B takeover bid, boosting investor confidence. ๐Ÿ”น New data on its Breast Cancer Index test reveals significant clinical impact. ๐Ÿ”น Trading at a P/S of 3.40X, it's cheaper than its five-year median. Is it time to dive in or wait for a dip? Full analysis here ๐Ÿ‘‰ https://www.zacks.com/commentary/2490517/hologic-climbs-13-in-a-month-how-should-you-play-the-stock?cid=sm-stocktwits-2-2490517-body&ADID=SYND_STOCKTWITS_TWEET_2_2490517_BODY
0 ยท Reply
ZacksResearch
ZacksResearch Jun. 9 at 1:33 PM
$HOLX surges 13.3% โ€” what's fueling the rally? ๐Ÿš€ ๐Ÿ”น Hologic turned down a non-binding $16.7B takeover bid, boosting investor confidence. ๐Ÿ”น New data on its Breast Cancer Index test reveals significant clinical impact. ๐Ÿ”น Trading at a P/S of 3.40X, it's cheaper than its five-year median. Is it time to dive in or wait for a dip? Full analysis here ๐Ÿ‘‰ https://www.zacks.com/commentary/2490517/hologic-climbs-13-in-a-month-how-should-you-play-the-stock?cid=sm-stocktwits-2-2490517-body&ADID=SYND_STOCKTWITS_TWEET_2_2490517_BODY
0 ยท Reply
ZacksResearch
ZacksResearch Jun. 9 at 11:45 AM
$HOLX up 13% in a month โ€” is this the start of something bigger? A rejected $16.7B buyout offer and fresh BCI data are driving momentum, but whatโ€™s the real investment case now? Full outlook breakdown here ๐Ÿ‘‰ https://www.zacks.com/stock/news/2490517/hologic-climbs-13-in-a-month-how-should-you-play-the-stock?cid=sm-stocktwits-2-2490517-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2490517_TEASER
0 ยท Reply
Thefunnyinvestor
Thefunnyinvestor Jun. 5 at 9:33 PM
0 ยท Reply
Truman2332
Truman2332 Jun. 4 at 3:01 PM
$HOLX still holding my short positionโ€ฆ being patient for mid 50s
1 ยท Reply
Traderoca
Traderoca Jun. 4 at 2:31 PM
0 ยท Reply